Literature DB >> 31317199

Generation of IgE-specific cytotoxic T lymphocytes as a novel immunotherapeutic approach for the treatment of allergic asthma.

Kangle Cui1, Yanna Chen1, Li Zhou2, Chunxia Yang3, Yao Du1, Weixing Shi1,4, Zeling Cai4, Jian Chen1.   

Abstract

INTRODUCTION: Overproduction of immunoglobulin E (IgE) by a subset of B cells plays a key role in the pathogenesis of allergic asthma. Anti-IgE monoclonal antibodies have been successfully used to treat the disease, but long-term application is required.
METHODS: For this study, cytotoxic T lymphocytes (CTLs) against IgE-producing B cells were generated ex vivo by stimulating naive CD8 T cells with IgE-derived peptides presented by Drosophila-derived artificial antigen-presenting cells. Based on the treatment of allergic asthma in mice, the inhibitive effect of this CTL on IgE responses and airway inflammation was determined with the enzyme-linked immunosorbent assay and histochemical method.
RESULTS: The IgE-specific CTLs effectively lysed target cells in vitro, while the adoptively transferred CTLs specifically inhibited IgE responses and airway inflammation in an asthmatic mouse model. The effect of IgE-specific CTLs is MHC (major histocompatibility complex) Class I-restricted and requires the expression of perforin.
CONCLUSION: IgE-specific CTLs generated ex vivo may provide a novel treatment for allergic asthma and lead to a new therapy for other immunological disorders. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  artificial antigen-presenting cells; cytotoxic T lymphocytes; immunoglobulin E; perforin

Mesh:

Substances:

Year:  2019        PMID: 31317199      PMCID: PMC7905137          DOI: 10.11622/smedj.2019068

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  41 in total

Review 1.  The pharmacological basis of anti-IgE therapy.

Authors:  T W Chang
Journal:  Nat Biotechnol       Date:  2000-02       Impact factor: 54.908

2.  Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Authors:  Marcus Maurer; Sabine Altrichter; Thomas Bieber; Tilo Biedermann; Matthias Bräutigam; Stefan Seyfried; Randolf Brehler; Jürgen Grabbe; Nicolas Hunzelmann; Thilo Jakob; Andreas Jung; Jörg Kleine-Tebbe; Martin Mempel; Michael Meurer; Kristian Reich; Franziska Ruëff; Knut Schäkel; Kaushik Sengupta; Christian Sieder; Jan C Simon; Bettina Wedi; Torsten Zuberbier; Vera Mahler; Petra Staubach
Journal:  J Allergy Clin Immunol       Date:  2011-06-02       Impact factor: 10.793

3.  Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.

Authors:  Gail M Gauvreau; Jeffrey M Harris; Louis-Philippe Boulet; Heleen Scheerens; J Mark Fitzgerald; Wendy S Putnam; Donald W Cockcroft; Beth E Davis; Richard Leigh; Yanan Zheng; Barbro Dahlén; Yehong Wang; Romeo Maciuca; Irvin Mayers; X Charlene Liao; Lawren C Wu; John G Matthews; Paul M O'Byrne
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

4.  Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.

Authors:  O Akbari; R H DeKruyff; D T Umetsu
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

Review 5.  Understanding the pathogenesis of allergic asthma using mouse models.

Authors:  K P Leong; D P Huston
Journal:  Ann Allergy Asthma Immunol       Date:  2001-08       Impact factor: 6.347

Review 6.  Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease.

Authors:  William E Berger
Journal:  Ann Allergy Asthma Immunol       Date:  2002-02       Impact factor: 6.347

7.  Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

Authors:  Jonathan Corren; Thomas Casale; Yamo Deniz; Mark Ashby
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

8.  Omalizumab: the evidence for its place in the treatment of allergic asthma.

Authors:  Diarmuid M McNicholl; Liam G Heaney
Journal:  Core Evid       Date:  2008-06

9.  MHC class I molecules with Superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs.

Authors:  Linda Wooldridge; Mathew Clement; Anna Lissina; Emily S J Edwards; Kristin Ladell; Julia Ekeruche; Rachel E Hewitt; Bruno Laugel; Emma Gostick; David K Cole; Reno Debets; Cor Berrevoets; John J Miles; Scott R Burrows; David A Price; Andrew K Sewell
Journal:  J Immunol       Date:  2010-02-26       Impact factor: 5.422

10.  Immunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in Mice.

Authors:  Cornelis K Mulder; Yun Dong; Humphrey F Brugghe; Hans A M Timmermans; Wichard Tilstra; Janny Westdijk; Elly van Riet; Harry van Steeg; Peter Hoogerhout; Ulrich L M Eisel
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

View more
  1 in total

1.  Bispecific T-Cell Engagers Targeting Membrane-Bound IgE.

Authors:  Aleksandra Rodak; Gerhard Stadlmayr; Katharina Stadlbauer; Dominic Lichtscheidl; Madhusudhan Reddy Bobbili; Florian Rüker; Gordana Wozniak-Knopp
Journal:  Biomedicines       Date:  2021-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.